Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 28Multiple Myeloma 26Lymphoma 26Lymphoma, Non-Hodgkin 21Leukemia, Myeloid, Acute 21Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Myelodysplastic Syndromes 19Lymphoma, Follicular 18Recurrence 16Lymphoma, B-Cell 16Leukemia 16Burkitt Lymphoma 16Lymphoma, Mantle-Cell 15Triple Negative Breast Neoplasms 14Ovarian Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Neuroblastoma 10Lymphoma, B-Cell, Marginal Zone 10Hodgkin Disease 10Sarcoma 8Melanoma 8Medulloblastoma 8Rhabdomyosarcoma 7Myeloproliferative Disorders 7Leukemia, Biphenotypic, Acute 7Carcinoma, Non-Small-Cell Lung 6Brain Neoplasms 6

Interventions

X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Biopsy 4ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Cyclophosphamide 2tazemetostat 1palbociclib 1olaparib 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1Vemurafenib 1Thiotepa 1Tacrolimus 1Sirolimus 1Pharmacogenomic Variants 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Melphalan 1Lenalidomide 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Histiocytosis, Langerhans-Cell × Cyclophosphamide × Clear all
NCT02574728 2026-03-02

AflacST1502

Emory University

Phase 2 Active not recruiting
46 enrolled
CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Columbia University

Phase 1/2 Active not recruiting
14 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Neutropenia, Severe Congenital, Autosomal Recessive 3, Bone Marrow Failure Disorders, Shwachman-Diamond Syndrome, Primary Immunodeficiency Diseases, Acquired Immunodeficiency Syndrome, Anemia, Aplastic, Anemia, Sickle Cell, Hemoglobinopathies, Histiocytosis, Langerhans-Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Histiocytosis, Anemia, Diamond-Blackfan, Lymphohistiocytosis, Hemophagocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Macrophage Activation Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡